Phase 2 Lupus Trial, Recruiting (NCT05029336)

Phase 2 Lupus Trial, Recruiting NCT05029336 Sponsor: Stephan Grupp MD PhD Condition: Lupus

Printed from Voxsanity (voxsanity.com.au) — NCT05029336 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lupus

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 8 and 25 years old at the time of joining the trial
You have been diagnosed with severe systemic sclerosis or severe systemic lupus erythematosus (a serious autoimmune disease), meeting specific medical criteria (confirm with trial site)
Your major organs (such as heart, lungs, kidneys, and liver) are functioning well enough to meet the trial's requirements (confirm with trial site)
You do not currently have any active infections that are not being treated

Who may not be able to join:

You have previously had a stem cell transplant or an organ transplant (such as a kidney or liver transplant)
You are currently pregnant
You are already taking part in another clinical trial testing an experimental drug, or you are currently taking certain medications used to treat autoimmune or rheumatic diseases that are not allowed in this trial (confirm with trial site)
You have a serious additional health condition that could make it unsafe for you to go through the treatment involved in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Caitlin Elgarten, MD, Children's Hospital of Philadelphia

Phone: (215) 590-5168

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05029336

Sponsor: Stephan Grupp MD PhD

Phase: Phase 2

Status: Recruiting

Condition: Lupus

Trial contact: (215) 590-5168

More information: https://clinicaltrials.gov/study/NCT05029336

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 8 and 25 years old at the time of joining the trial
You have been diagnosed with severe systemic sclerosis or severe systemic lupus erythematosus (a serious autoimmune disease), meeting specific medical criteria (confirm with trial site)
Your major organs (such as heart, lungs, kidneys, and liver) are functioning well enough to meet the trial's requirements (confirm with trial site)
You do not currently have any active infections that are not being treated

Who may not be able to join:

You have previously had a stem cell transplant or an organ transplant (such as a kidney or liver transplant)
You are currently pregnant
You are already taking part in another clinical trial testing an experimental drug, or you are currently taking certain medications used to treat autoimmune or rheumatic diseases that are not allowed in this trial (confirm with trial site)
You have a serious additional health condition that could make it unsafe for you to go through the treatment involved in this trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Stephan Grupp MD PhD

Registry

ClinicalTrials.gov

Start date

1 March 2026

Est. completion

1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Two-year progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov